Showing results (21-30 of 72) with videos related to
Sort By:
Pageof 8
Annals of Hematology|December 6, 2024
Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcersHarish Eswaran, Samuel Wilson, Jane Little, et al.The American Journal of the Medical Sciences|June 18, 2004
Extensive fibromuscular dysplasia in a patient with Parkinson diseaseThomas H Wang, Matthew Mauro, J Charles Jennette, et al.Vascular Medicine (London, England)|October 26, 2022
Livedoid vasculopathy: A review with focus on terminology and pathogenesisHarish Eswaran, Paul Googe, Priyanka Vedak, et al.The American Journal of Medicine|February 5, 2017
Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical GuidanceKarlyn A Martin, Craig R Lee, Timothy M Farrell, et al.Current Opinion in Obstetrics & Gynecology|June 3, 2016
Management considerations for patients with uterine fibroids and concurrent venous thromboembolismJanelle K Moulder, Matthew T Siedhoff, Sara R Till, et al.Gynecologic Oncology Reports|February 10, 2017
Leukocytosis due to markedly elevated granulocyte-colony stimulating factor levels in a patient with endometrial cancer: Case report and literature reviewLeslie H Clark, Stephan Moll, Damon Houghton, et al.Environmental Science & Technology|December 28, 2012
Price corrected domestic technology assumption--a method to assess pollution embodied in trade using primary official statistics only. With a case on CO2 emissions embodied in imports to EuropeArnold Tukker, Arjan de Koning, Richard Wood, et al.American Journal of Hematology|March 22, 2006
False-negative factor V Leiden genetic testing in a patient with recurrent deep venous thrombosisEdward N Libby, Jessica K Booker, Margaret L Gulley, et al.Research and Practice in Thrombosis and Haemostasis|July 7, 2023
Advanced practice provider-led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilizationCassiopeia Frank, Raj Kasthuri, Nigel S Key, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devicesStephan Moll, Peter Kenyon, Luigi Bertoli, et al.Pageof 8